The c-erB-2 oncogene amplification by competitive PCR in aneuploid cell clones flow sorted from breast cancer samples

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 6, 1999, Pages 649-654

  Vona, Giovanna ^a   Caldini, Anna ^b   Sestini, Roberta ^a   Rapi, Stefano ^b   Bianchi, Simonetta ^a   Fanelli, Alessandra ^b   Pazzagli, Mario ^a   Orlando, Claudio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Aneuploidy; Breast cancer; Competitive PCR; DNA index; Flow sorting; Oncogen amplification

Indexed keywords

ANEUPLOIDY; ARTICLE; BREAST CANCER; CELL CLONE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE NUMBER; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; BREAST TUMOR; COMPARATIVE STUDY; GENE AMPLIFICATION; GENETICS; METHODOLOGY; PATHOLOGY; PROGNOSIS; PROTO ONCOGENE;

ANEUPLOIDY; BREAST NEOPLASMS; CLONE CELLS; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 0033144470     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1999.101     Document Type: Article

References (41)

1. Dickinson RB, Lippman ME. Growth factors in breast cancer. Endocr Rev 1995; 16:559-89.
2. Alitalo K, Schwab M. Oncogene amplification in tumor cells. Adv Cancer Res 1986; 47:235-81.
3. Wolman SR, Pauley RJ, Mohamed AN, Dawson PJ, Visscher DW, Sarkar FH. Genetic markers as prognostic indicators in breast cancer. Cancer 1992; 70:1765-74.
4. Borg A, Tandon AK, Siggurdsson H, Clark GM, Ferno M, Fuqua SAW, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50:4332-7.
5. Lönn U, Lönn S, Nilsson B, Stenkvist B. Prognostic value of erbB-2 and myc amplification in breast cancer imprints. Cancer 1995; 75:2681-7.
6. Perren, T. c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 1991; 63:328-32.
7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82.
8. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keit DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12.
9. Ali IU, Campbell G, Lidereau R, Callahan R. Amplification of c-erbB-2 and aggressive human breast tumors. Science 1988; 240:1795-6.
10. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991; 51:944-8.
11. Heintz NH, Leslie KO, Rogers LA, Howard PL. Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 1990; 114:160-3.
12. Zhou DJ, Ahuja H, Cline MJ. Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 1989; 45:360-3.
13. Harlow SP, Stewart CC. Quantitation of c-myc gene amplification by a competitive PCR assay system. PCR Meth Appl 1993; 3:163-8.
14. Li BDL, Harlow SP, Budnick RM, Sheedy DL, Stewart CC. Detection of HER-2/neu oncogene amplification in flow cytometry-sorted breast ductal cells by competitive polymerase chain reaction. Cancer 1994; 73:2771-8.
15. Orlando C. Sestini R, Vona G, Pinzani P, Blanchi S, Giacca M, et al. Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique. J Urol 1996; 156:2089-93.
16. Sestini R, Orlando C, Zentilin L, Gelmini S, Pinzani P, Bianchi S, et al. Measuring c-erbB-2 oncogene amplification in fresh and paraffin-embedded tumors by competitive polymerase chain reaction. Clin Chem 1994; 40:630-6.
17. Sestini R, Orlando C, Zentilin L, Lami D, Gelmini S, Pinzani P, et al. Measurement of gene amplification for c-erbB-2, c-myc, epidermal growth factor receptor, int-2 and N-myc by quantitative PCR with a multiple competitor template. Clin Chem 1995; 41:826-32.
18. Sestini R, Orlando C, Peri A, Tricarico C, Pazzagli M, Serio M, et al. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors by competitive reverse transcription polymerase chain reaction. Clin Cancer Res 1996; 2:1757-65.
19. Abeln ECA, Corver WE, Kuipers-Dijkshoorn NJ, Fleuren GJ, Cornelisse CJ. Molecular genetic analysis of flow-sorted ovarian tumor cells: improved detection of loss of heterozygosity. Br J Cancer 1994; 70:255-62.
20. Burmer GC, Rabinovitch PS, Haggitt RC, Crispin DA, Brentnail TA, Kolli VR, et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 1992; 103:1602-10.
21. Giaretti W, Pujic N, Rapallo A, Nigro S, Di Vinci A, Geido E, et al. K-ras G-C and G-T transversions correlate with DNA aneuploidy in colorectal adenomas. Gastroenterology 1995; 108:1040-7.
22. Rapi S, Caldini A, Fanelli A, Berti P, Anichini E, Caligiani F, et al. Flow cytometric measurement of DNA content in human solid tumors: a comparison with cytogenetics. Cytometry (Communications in Clinical Cytometry) 1996; 26:192-7.
23. Medley WH, Clarck GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review on the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 1993; 14:482-5.
24. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque RE, Hedley DW, et al. Guidelines for implementation of clinical flow cytometry. Cytometry 1993; 14:472-7.
25. Sambrook J, Fritsch EF, Maniatis T, editors. Molecular cloning. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989:16-19.
26. Orlando C, Sestini R, Zentilin L, Gelmini S, Pinzani P, Giacca M, et al. Image analysis in quantitative PCR. An application for the measurement of c-erbB-2 amplification in DNA from human tumors. J Biolum Chemilum 1994; 9:223-8.
27. Bianchi S, Paglierani M, Zampi G, Cardona G, Cataliotti L, Bonardi R, et al. Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer 1993; 67:625-9.
28. Soomro S, Shousha S, Taylor S, Shepard HM, Feldmann M. c-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol 1991; 44:2114.
29. HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res 1995; 55:5400-7.
30. Stàl O, Sullivan S, Sun XF, Wingren S, Nordenskjöld B. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. Cytometry 1994; 16:160-8.
31. Singleton TP, Strickler JG. Clinical and pathological significance of c-erbB-2 (HER-2/neu) oncogene. Pathol Ann 1992; 27:165-90.
32. Callahan R, Campbell G. Mutations in human breast cancer: an overview. J Natl Cancer Inst 1989; 1:1780-6.
33. Bandyopadhyay D, Dani HD, Samant UC, Redkar AA, Mittra I. Correlation between c-erbB-2 oncogene amplification and the expression of its mRNA and protein in human breast carcinoma. Oncology 1992; 49:9-14.
34. Hubbard AL, Doris CP, Thompson AM, Chetty U, Anderson TJ. Critical determination of the frequency of c-erbB-2 amplification in breast cancer. Br J Cancer 1994; 70: 434-9.
35. Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991; 63:601-8.
36. Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994; 54:5675-82.
37. Tanner MM, Karhu RA, Nupponen NN, Borg A, Baldetorp B, Pejovic T, et al. Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. Am J Pathol 1998; 153:191-9.
38. Giaretti W, Rapallo A, Geido E, Sciutto A, Merlo F, Risio M, et al. Specific K-ras2 mutations in human sporadic colorectal adenomas are associated with DNA near-diploid aneuploidy and inhibition of proliferation. Am J Pathol 1998; 153:1201-9.
39. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996; 13:1359-65.
40. Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, et al. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 1998; 16:2087-94.
41. Tetu B, Brisson J, Plante V, Bernard P. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 1998; 11:823-30.